AKT1 and prostate cancer: (9) found that, in prostate cancer, cancer-IgG staining was stronger in specimens at advanced clinical stages; androgen deprivation therapy for prostate cancer–induced cancer-IgG expression maintained stemness and facilitated cancer progression through mitogen-activated protein kinase/extracellular signal–regulated kinase and AKT in prostate cancer.